• Lexaria’s patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions
• The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors
• Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD
• California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1
• Four new patents have been added to Lexaria’s portfolio, bringing the total to 32 granted patents and more pending worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is improving how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules through its patented DehydraTECH(TM) technology. DehydraTECH can be used with a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions.

Lexaria is focusing its ongoing research and development efforts on advancing product candidates across several key segments, including nicotine replacement, cannabidiol (“CBD”) for hypertension, diabetes and epilepsy, antivirals, human hormones, and phosphodiesterase type 5 (“PDE5”) inhibitors.

The company recently announced the completion of its diabetes animal study DIAB-A22-1, with at least three positive outcomes, including weight loss in obese diabetic-conditioned animals, with improved triglycerides and cholesterol levels. Lexaria plans to conduct additional investigations to learn what an optimum DehydraTECH-CBD dose related to both weight loss and increased physical activity might be, considering that the higher dose studied may have created sedative-like effects of CBD triggering hypolocomotion, which has been observed upon high systemic exposure (https://ibn.fm/zCd08).

Separately, Lexaria has also announced that California-based InClin, Inc. has been awarded the contract for clinical research organization (“CRO”) services for the expected upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study HYPER-H23-1 with its DehydraTECH-CBD.

The study is entitled ‘A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension’. The primary objective of this study will be to evaluate the safety and tolerability in up to 120 hypertensive patients, with secondary objectives of efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing.

InClin is preparing for the study start-up, and Lexaria is expected to begin with patient dosing as soon as possible after the FDA IND filing and review are complete. The company anticipates filing the IND this summer, with FDA authorization likely to follow within about 60 days – resulting in Phase 1b trial commencement of patient dosing as early as October 2023.

According to a recent press release, InClin’s study start-up services include, but are not limited to, clinical site evaluation and selection, personnel and site training, project management, clinical database design and management, quality assurance support, medical writing, study documentation creation, biostatistics and programming, support vendor coordination, Independent Review Board submissions and more (https://ibn.fm/KqAAL).

At the end of April, Lexaria announced that it had received notification of being awarded or allowed four new patents, bringing the total up to 32 granted or allowed patents and even more pending worldwide. The new patents include the United States, Japan, Australia, and Canada. The patent in the U.S. will be the first for Patent Family #21: Compositions and Methods of Treating Hypertension, which the company believes will be particularly important related to its pursuit of utilizing DehydraTECH-CBD concerning the company’s upcoming FDA IND application (https://ibn.fm/XYAPO).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Web3 Berlin is set to host an annual event on the 10th and 11th of June at the Estrel Congress Center. The conference promises to be an unforgettable experience where attendees can focus on networking, onboarding, and education about Web3, and most importantly, it aims to be the biggest Crypto & NFT event in Europe.

The conference has already established itself as a major event on the Web3 calendar, having signed up more than 80 partners, including leading companies and organizations in the industry, such as Solana, Dash, Ramp, KuCoin, VeChain, Celo or Fantom Foundation.

“We are aiming to create an event accessible to as many people as possible, hence a low ticket price threshold. Inclusivity and onboarding new users is the key – with 7,000 attendees expected, this is an excellent opportunity to reach a highly engaged and relevant audience,” said one of the organizers.

The conference will feature a mix of keynote presentations, panel discussions, and satellite events. The sessions will cover a range of topics from blockchain technology, decentralized finance (“DeFi”), non-fungible tokens (“NFTs”), crypto gaming, and more. The speakers will include some of the brightest minds in the industry, providing attendees with valuable insights into the latest trends, best practices, and innovative ideas in the field.

The conference will also offer a range of networking opportunities, allowing attendees to connect with like-minded individuals, startups, and established companies in the industry. Participants will be able to engage in one-on-one conversations, join roundtable discussions, and attend social events, providing an opportunity to forge new relationships and collaborate with others in the space.

The conference will be an excellent opportunity for attendees to gain knowledge, exchange ideas, and collaborate with the best and brightest minds in the industry. The focus on inclusivity and accessibility means that the conference is an ideal venue for newcomers to the field, as well as seasoned professionals looking to expand their knowledge and network.

Web3 Berlin is not only a great opportunity to learn about the latest trends and innovations in the industry, but it is also a chance to be a part of the decentralized future. With the growing adoption of blockchain technology and the increasing interest in cryptocurrencies, the conference provides a platform for individuals and businesses to explore the potential of Web3 and its impact on the future of finance, technology, and society as a whole.

Tickets for Web3 Berlin are available now on the event’s website, starting from 25,00€ for Standard Tickets and 350,00€ for VIP Access. VIP tickets provide extra perks, such as access to VIP Networking Zones, Food&Drinks Catering, and other limited benefits.

Website – https://berlinweb3.com
Twitter – https://twitter.com/berlinweb3com 

• The equity report noted CISO’s triple-digit Q4 growth in several areas
• “We expect Cerberus to build on its momentum in making headway into larger enterprise customers,” report observes
• Cybersecurity talent shortage landscape could be “highly favorable” to Cerberus

A recent Cantor Fitzgerald equity research report is high on CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., a leading provider of global cybersecurity and compliance. Noting that the company is strategically positioned to fill the cybersecurity talent shortage gap, Cantor Research gave CISO an overweight rating and a $2 price target (https://nnw.fm/EP1WX).

“Reiterate overweight and moderating our 12-month price target from $5 to $2 due to volatile trading condition; however, growth fundamentals intact,” the report stated. “We believe the modest multiple is justified or even undervalues CISO given its leadership position at scale in the cybersecurity services space, hyper-growth revenue acceleration, a large and expanding TAM, a favorable macro tailwind on continued talent shortages and an improving financial profile.”

The equity report noted CISO’s significant Q4 growth, including revenue of $14.7 million, up 150.3% year-over-year, ahead of Cantor’s estimate of $13.2 million; security managed services growth of 161.8% year-over-year to $12.4 million at a margin of 61.8%; and growth of professional services totaling 102.6% year-over-year to $2.3 million at a margin of 83.2%.

“Cerberus historically bills customers on a monthly basis; however, the company has been selling larger multiyear enterprise contracts in 2022, resulting in a significant acceleration in deferred revenue,” Cantor reported. “We expect Cerberus to build on its momentum in making headway into larger enterprise customers, and therefore, we anticipate deferred revenue balance to build going forward. Free cash flow was at -$2.8 million, strongly ahead of our estimate at -$5.9 million, driven by a more efficient operating margin of -64.5% (vs. our estimate of -67.8%) on the heels of better cost-optimization measures.”

Cantor also noted that the cybersecurity talent shortage landscape could be “highly favorable” to Cerberus. “Management has pointed out 62% of chief information security officers (‘CISOs’) are expecting to face talent shortfall over the next five years and 95% of CISOs don’t believe the skills shortage gap has improved at all over the last couple of years,” the report observed. “The combination of these industry factors is driving a favorable recurring revenue of 62% on a TTM basis and a new logo retention rate of over 90%.

“Cerberus Cyber Sentinel Corporation is in the process of changing its company’s name to CISO Global Inc. as part of its rebranding effort to better align with its mission to ‘bring cybersecurity professionals together on a global basis,’” Cantor continued. “In summary, we believe team CISO has completed its first year as a public company in a positive note despite the challenging macro environment and volatile trading conditions repeatedly experienced by larger public traded peers, and we envision the growth momentum will carry through into 2023E.”

In addition, the report provided an overview of CISO’s financial metrics/KPIs; acquisitions strategy, including the company’s January 2023 agreement to acquire RAN Security, a secured managed services firm based in Buenos Aires, Argentina; and its healthy deals pipeline as further explanation of the high rating. The report also mentioned the appointment of Kyle Young, recently the company’s director of operations, to interim COO and noted the competitive cybersecurity landscape as part of its thorough review of CISO Global.

CISO is gaining recognition as a leading provider of global cybersecurity and compliance as it rapidly expands by acquiring world-class cybersecurity, secured-managed services and compliance companies. These acquisitions bring top-tier talent to the CISO table, enabling the company to utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• In September 2022, XESP announced its new business strategy of providing managed digital engagement services through its DE2 platform
• In February 2023, XESP named Peter Hager as its President and CEO
• The company’s digital engagement technology has helped dozens of organizations achieve growth results up to nine-times the industry standard
• XESP is a market disrupter for B2B companies looking for $10M+ in additive growth per year

Electronic Servitor Publication Network (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine(TM). This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine(TM) ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.

Technology

Electronic Servitor Publication Network’s Digital Engagement Engine(TM) utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine(TM) provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by ReportLinker.com, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Positive preclinical data was presented for the NPRL2 tumor suppressor gene
• The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models
• Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer
• ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer

Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which is a tumor suppressor gene. The presentation was given at the 2023 American Association of Cancer Research (“AACR”) annual meeting, which took place from April 14-18, 2023, in Orlando, Florida.

The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models.

Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic effect without the risk of toxicity often associated with viral delivery systems.

“The preclinical data also provide further evidence that the ONCOPREX(R) Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA(R),” said Rodney Varner, President and Chief Executive Officer of Genprex, said (https://ibn.fm/9PtRa). “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”

The company’s cancer-fighting technologies may provide new treatment options for large cancer patient populations, such as those with lung cancer.

The company’s oncology pipeline aims to reprogram the course of cancer. Genprex is evaluating its proprietary, non-viral ONCOPREX(R) delivery system, which is believed to be the first systemic gene therapy delivery platform used for cancer in humans, in its REQORSA clinical programs.

“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA(R) clinical oncology programs, presented before some of the world’s leading cancer researchers,” Varner also said. “The use of the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”

In addition to oncology, Genprex is also working on therapies for diabetes, another large patient population with limited treatment options. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes to the pancreas. The candidates in this pipeline have shown in preclinical studies in mice and non-human primates, the potential to stabilize glucose levels and reduce insulin requirements. Genprex’s R&D pipeline for diabetes includes its preclinical candidates, GPX-002 for Type 1 diabetes and GPX-003 for Type 2 diabetes.

Even with certain advancements in treatment, the quality of life remains highly compromised for many with diabetes. Diabetes gene therapies like those being developed by Genprex could hold the potential to provide long-term effectiveness and completely change the course of the disease – enhancing the quality of life for those living with the disease.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Ucore has set out to capitalize on critical mid-market separation of REE through its transformative RapidSX(TM) technology in a bid to address China’s dominance in the rare oxide market
• The company is confident in its approach and has even committed to investing $75 million in CapEx over the next four years to establish North America’s first modern REE separation and purification facility

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals (“CM”) separation technology company, understands the potential of the rare oxide market and the stake that China currently holds. According to CEO Pat Ryan, this industry is expected to reach $32 billion by the decade’s end. However, with China controlling 90% of this sector, there has been a push by other countries to cut down dependence and seek out alternatives which, in turn, do away with the risks associated with China’s dominance (https://ibn.fm/WdTPC).

Ucore has stepped up, ultimately playing an integral role in establishing a comprehensive North American critical metals supply chain. Through its transformative technology, RapidSX(TM), the company has been able to capitalize on critical mid-market separation of rare earth elements (“REE”) or its lack thereof. In addition, having streamlined its process of arranging work relationships upstream and dealing with downstream customers, the company has managed to carve out a decent market share for itself, with the goal of taking up 20% of the ex-China rare oxide market in the coming years (https://ibn.fm/BRJu9).

The company is confident in its approach and has even committed to investing $75 million in capital expenditure (“CapEx”) over the next four years to establish North America’s first modern REE separation and purification facility. Located in England Airpark Community in Alexandria, Louisiana, this facility will create at least 100 family-wage paying jobs and improve business opportunities for the area (https://ibn.fm/SFRXK). The investment will build on the $10 million already invested in Ucore’s demonstration plant in Kingston, Ontario, with additional plans to engineer a second and third commercial plant to handle all the expected capacity.

Ucore is positioning itself to fulfill North America’s unmet REE needs through commercial production plants. It is doing what its competitors have not, thereby defining the industry and positioning itself as an undisputed market leader. As it continues to carve out its market share, Ucore is placing North America on the map, defining its REE self-reliance, and creating employment and business opportunities while at it.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

For over a decade, FinovateSpring has attracted the best and brightest on and off the stage, including decision-makers from across the financial services spectrum, including banks, brokerages, card issuers, payment providers, investment companies, insurance providers, and everything in between. This year’s FinovateSpring event continues the tradition, but this time in a new venue – Marriot Marquis San Francisco.

More than 50+ live demos are scheduled for FinovateSpring, spread across two days on May 23-25, 2023 – themed to include personal/retail, business, backend/enabling, and outside-a-box technology. These demos are hand-selected to showcase their services and solutions, not just pitch them, showing how their tech works to attendees and providing value as to why they should be implemented within an organization.

Audiences who attend FinovateSpring are unlike those at any other fintech event – where most high attendance numbers are padded with junior-level staff. Finovate’s audience is created with quality, not quantity, in mind. Bringing together the people who matter in the fintech industry – with senior innovators leading the fintech revolution, senior decision-makers from leading financial institutions, and senior investors from VC firms looking for their next opportunity.

With each of the top ten banks in the nation signed up to attend, FinovateSpring expects over 1,200 senior fintech attendees, 50+ innovative fintech demos, 270+ financial institutions, 200+ C-level attendees, and press and media coverage from over 75 influential outlets.

Who should attend?

• Decision-makers from across the financial services industry, including banks, brokerages, card issuers, payment providers, investment companies, insurance providers, and more
• Execs and founders of fintech and general technology companies
• VC, corporate, private equity, and angel investors interested in funding fintech companies
• Influential research analysts, press, and consultants from large financial services practices
• Leading government, regulator, and industry association representatives focused on the emerging fintech sector

In times of unprecedented change, making new industry connections is vital. FinovateSpring’s unique high-impact networking sessions are at the heart of its events. Its smart matchmaking tool makes it easier to search, find, and engage with the people who can move businesses forward. Attendees are invited to grow their networks intelligently and effectively at this year’s FinovateSpring.

To learn more, please visit https://ibn.fm/rTYQ6.

In October 2018, Canada became the first developed country to legalize recreational cannabis for adult use (https://ibn.fm/xofpU). Aimed at curbing the illicit trade of the drug and launching a new source of economic growth, this move is playing a significant role in the economy. For instance, Deloitte’s study, which considered the direct, indirect, and induced economic activities, estimated that the industry had contributed US$43.5 billion to Canada’s economy between legalization and 2021 (https://ibn.fm/QdHpz).

And as the country counts down to the fifth anniversary this October, the figure is expected to be higher, making the upcoming Lift Toronto 2023 Cannabis Conference & Expo the perfect setting to take stock of the progress so far, as well as find ways to draw even more value while pushing the industry forward. The event will be held at the expansive Metro Toronto Convention Centre from June 1-3, 2023 (https://ibn.fm/SY7V3).

The organizer, Lift Events & Experiences, has curated Lift Toronto 2023 to lift the cannabis industry and community from day one. The event will kick off with the Lift Cannabis Business Conference (“LCBC”), a strategy-focused, advocacy-oriented business and community leadership forum. The LCBC will focus on conversations that drive the industry’s momentum forward, as well as help players overcome systemic challenges and advance innovative business and regulatory solutions that will generate meaningful change and sustainable growth in Canada’s cannabis industry.

The conversations will be spearheaded by an outstanding roster of speakers who will share insights during planned keynote presentations and panel discussions, with each session “carefully curated to energize, inspire, educate, and motivate all our audiences from across the entire cannabis community,” according to Barry Smith, Canadian Content Director at Lift Events & Experiences (https://ibn.fm/5e6b9).

The keynote presentation delivered by David Lobo, President & CEO, Ontario Cannabis Store, will look at the entirety of Canada’s cannabis industry, providing a review and updates on its priorities and progress. Next, the CEOs Perspective, will feature Niel Marotta, CEO & Founder, INDIVA; David Schwede, CEO, Heritage Cannabis; Marcie Kiziak, CEO, Nova Cannabis; and John Fowler, CEO, Muskoka Grown & Dank Craft, sharing insights based on their perspectives as leaders in the space. Specifically, they will discuss consumers’ wants, competitive strategy, growing moratoriums and market restraints, and building cannabis brands. 

And what about the international markets? The conference agenda will unpack that topic with a dedicated international review session. Other themes and topics on the agenda include business funding; extracts, concentrates, and processing; cannabis marketing; and cannabis retailing (https://ibn.fm/UqccW).

The second and third day, June 2 & 3, are expo days geared toward enabling hundreds of exhibiting companies, drawn from across the entire cannabis ecosystem, to interact with consumers as well as growers, licensed producers, retailers, budtenders, brands, and investors. Plus, the expo days will provide excellent networking opportunities, with designated networking areas, both indoors and outdoors. Attendees can also expect Lift’s signature surprises and uplifting moments, live music, and cameo appearances, culminating in an official after party on the evening of Saturday, June 3.

For more information and to purchase your ticket, visit https://ibn.fm/SY7V3.

• Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1
• InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more
• Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer
• HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of its patented DehydraTECH(TM)-processed CBD

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the awarding of the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. This move is in line with the company’s upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study, HYPER-H23-1 that will explore the potential of its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) for the treatment of hypertension (https://ibn.fm/V6RBS).

The study will build on five previous Lexaria studies dating back to 2018, which were each successful, evidencing significant reductions in resting blood pressure over acute and multi-week dosing regimens on 134 healthy and hypertensive persons. The studies also showed that DehydraTECH-CBD produced zero serious adverse events, highlighting its potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics. The uniqueness of this product is further evidenced by its superior ability to reduce blood pressure over other oral CBD formulations currently in the market.

InClin will help with the study in the form of clinical site evaluation and selection, project management, personnel, site training, clinical database design and management, and quality assurance support. It will also be responsible for medical writing, study documentation creation, biostatistics and programming, support vendor coordination, Independent Review Board (“IRB”) submissions, and more. Study start-up is about to begin, with patient dosing set to kick off as soon as the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer. Upon the filing, Lexaria hopes for FDA authorization within about 60 days, after which the Phase 1(b) trial aggressively targeting the commencement of patient dosing will kick off.

HYPER-H23-1, titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will be Lexaria’s most ambitious study yet. Its primary objective will be to evaluate safety and tolerability in up to 120 hypertensive patients, with secondary objectives including efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing. Its successful completion will inch Lexaria closer to FDA approval of its DehydraTECH-CBD. But, more importantly, it will stamp Lexaria’s position as a leader in its space, having come up with a product that achieves a sustained decrease in resting blood pressure following multiple weeks of oral CBD dosing.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The European Biogas Association estimates the EU region could rise to 133-283 billion euros annually by 2050
• EverGen Infrastructure provides a whole-system renewable natural gas solution that converts organic waste to valuable products while reducing pollutive emissions
• EverGen has assets in three Canadian provinces, including operational facilities in B.C. and Alberta and partnerships with FortisBC, small businesses, and municipalities

Organic waste, which includes agricultural residues, food waste, and yard waste, was historically an infinite liability bound for landfills and incinerators. Thanks to modern technologies like those of EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), that same waste is now a valuable asset that can be used to create renewable products such as biofuels, bioplastics, fertilizers, and more. By diverting organic waste from landfills and converting it into renewable goods, businesses can reduce their environmental impact, create new revenue streams, and promote a more sustainable economy.

Biomethane is a renewable energy source that is produced from organic matter such as animal waste, food waste, and sewage. It is a clean and sustainable alternative to fossil fuels, and it has the potential to significantly reduce greenhouse gas emissions by capturing and utilizing methane that would otherwise be released into the atmosphere. In addition to its environmental benefits, biomethane also has several whole-system benefits that make it an attractive option for businesses and governments.

On that point, a report titled, “Beyond energy: monetising biomethane’s whole system benefits” from the European Biogas Association shows that, in 2030, the whole system benefits of biomethane production in the EU27 + UK could range from 38-78 billion euros each year. By 2050, the report shows the benefits rising to 133-283 billion euros annually by 2050. Moreover, the report states that the values, which are comparable to the gross domestic products of Luxembourg and Finland, are likely underestimated.

Implementing anaerobic digestion (“AD”) to today’s technology adds even more value, according to the report, to the tune of 84-175 euros per megawatt hour (€/MWh) of biomethane produced. AD is an alternative way to treat manure while producing biogas as a renewable fuel. Highly scientific, increasing the efficiency of AD performance is determined through accurate prediction of biogas yield in different working conditions.

One of the most significant benefits of biomethane is its ability to generate revenue for farmers and waste management companies. By converting organic waste into biomethane, these businesses can create a new revenue stream that can help offset the costs of waste disposal and other expenses. In addition, biomethane can be sold to utilities and other energy providers, providing a reliable source of income for these businesses.

That is where EverGen is establishing itself as “Canada’s Renewable Natural Gas Infrastructure Platform.” The British Columbia-based company provides whole-system solutions for converting organic waste into biofuel for energy or digestate for products such as premium fertilizer or animal bedding. The company operates Sea to Sky Soils and Pacific Coast Renewables organics processing facilities and Fraser Valley Biogas, a RNG facility, in British Columbia. To the east, it has a 67% ownership in GrowTEC, an operational RNG facility in Alberta, and a 50% ownership in Project Radius, one of the most ambitious RNG projects in Ontario.

With investments in the three provinces, EverGen has contracts with local businesses and municipalities to redirect waste from conventional disposal. The company is also a partner to FortisBC, a major Canadian utility, where the renewable natural gas (“RNG”) produced through EverGen systems is sold to FortisBC, which pumps it into its existing natural gas pipelines. RNG is a renewable biomethane that is indistinguishable from conventional natural gas piped from the ground by energy companies.

By capturing these emissions and transforming them into RNG, then combusting them into CO2, the overall greenhouse gases (“GHG”) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

Biomethane offers a number of benefits for the energy sector. As a renewable energy source, biomethane can help reduce reliance on fossil fuels and provide a stable source of energy that is not subject to the same price fluctuations as oil and gas. In addition, biomethane can be used to generate electricity, heat buildings, and power vehicles, making it a versatile and flexible energy source.

Perhaps one of the most promising benefits of biomethane is its potential to support a circular economy. By converting organic waste into a valuable resource, biomethane can help close the loop on waste and create a more sustainable system of production and consumption. This can help reduce the environmental impact of waste disposal and create a more efficient use of resources.

As with any emerging technology, there are challenges to widespread adoption – such as logistical issues in areas where natural gas infrastructure isn’t well established and upfront capital costs. To address these challenges, governments and businesses are working collaboratively on policies and incentives to encourage adoption of renewable technologies. In short, turning organic waste into biomethane and agricultural products is highly attractive compared to fossil fuels and landfills that contribute to climate change today with the added perk of generating revenue for farmers and waste management companies, to creating jobs and promoting economic growth.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF